FDA advisers recommend full approval of Pfizer's COVID-19 pill Paxlovid for high-risk adults.
TL;DR Summary
Pfizer's COVID-19 pill, Paxlovid, has received a positive vote from a panel of outside experts, clearing the way for full regulatory approval by the FDA. The medication has been used by millions of Americans since the FDA granted it emergency use authorization in late 2021. The panel agreed that Paxlovid remains a safe and effective treatment for high-risk adults with COVID-19 who are more likely to face hospitalization and death due to the virus. The FDA said using Paxlovid in high-risk patients could prevent 1,500 COVID-19 deaths and 13,000 hospitalizations per week.
- COVID-19 pill Paxlovid moves closer to full FDA approval The Associated Press
- FDA advisers vote in support of Paxlovid approval for Covid-19 treatment in high-risk adults CNN
- F.D.A. Advisers Endorse Paxlovid’s Benefits as a Covid Treatment The New York Times
- FDA advisors recommend full approval of Pfizer Covid treatment Paxlovid for adults 50 and over and other high-risk people CNBC
- Pfizer wins FDA panel vote for full approval of COVID pill (NYSE:PFE) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
12
Time Saved
2 min
vs 3 min read
Condensed
83%
547 → 92 words
Want the full story? Read the original article
Read on The Associated Press